Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease

Bibliography

• BIRKMAYER W, HORNYKIEWICZ O: [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien. Klin. Wochenschr. (1961) 73:787-788.
   PubMedGoogle Scholar
• COTZIAS GC, PAPAVASILIOU PS, GELLENE R: Modification of Parkinsonism – chronic treatment with L-dopa. N. Engl. J. Med. (1969) 280(7):337-345.
   PubMed Web of Science ®Google Scholar
• FOLEY P, MIZUNO Y, NAGATSU T et al.: The L-DOPA story – an early Japanese contribution. Parkinsonism Relat. Disord. (2000) 6(1):1.
   Web of Science ®Google Scholar
• FAHN S, OAKES D, SHOULSON I et al.: Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med. (2004) 351(24):2498-2508.
   PubMed Web of Science ®Google Scholar
• HUGHES AJ, DANIEL SE, KILFORD L, LEES AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry (1992) 55(3):181-184.
   PubMed Web of Science ®Google Scholar
• MÜLLER T, BENZ S, BORNKE C, RUSS H, PRZUNTEK H: Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson’s disease. J. Neural Transm. (2003) 110(6):603-609.
   PubMed Web of Science ®Google Scholar
• GOETZE O, WIECZOREK J, MUELLER T, PRZUNTEK H, SCHMIDT WE, WOITALLA D: Impaired gastric emptying of a solid test meal in patients with Parkinson’s disease using 13C-sodium octanoate breath test. Neurosci. Lett. (2005) 375(3):170-173.
   PubMed Web of Science ®Google Scholar
• MUHLACK S, WOITALLA D, WELNIC J, TWIEHAUS S, PRZUNTEK H, MULLER T: Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s disease. Neurosci. Lett. (2004) 363(3):284-287.
   PubMed Web of Science ®Google Scholar
• MULLER T, WOITALLA D, SAFT C, KUHN W: Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat. Disord. (2000) 6(3):171-173.
   PubMed Web of Science ®Google Scholar
• MURATA M, MIZUSAWA H, YAMANOUCHI H, KANAZAWA I: Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J. Neural Transm. (1996) 103(10):1177-1185.
   PubMed Web of Science ®Google Scholar
• KURLAN R, ROTHFIELD KP, WOODWARD WR et al.: Erratic gastric emptying of levodopa may cause ‘random’ fluctuations of parkinsonian mobility. Neurology (1988) 38(3):419-421.
   PubMed Web of Science ®Google Scholar
• OGAWA N: Factors affecting levodopa effects in Parkinson’s disease. Acta Med. Okayama (2000) 54(3):95-101.
   PubMed Web of Science ®Google Scholar
• FAHN S: Controversies in the therapy of Parkinson’s disease. Adv. Neurol. (1996) 69:477-486.
   PubMedGoogle Scholar
• MÜLLER T: Dopaminergic substitution in Parkinson’s disease. Expert. Opin. Pharmacother. (2002) 3(10):1393-1403.
   PubMedGoogle Scholar
• SMITH LA, JACKSON MJ, AL BARGHOUTHY G et al.: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. (2005) 20(3):306-314.
   PubMed Web of Science ®Google Scholar
• CHASE TN, OH JD, BLANCHET PJ: Neostriatal mechanisms in Parkinson’s disease. Neurology (1998) 51(2 Suppl. 2):S30-S35.
   Google Scholar
• JENNER P: Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology (2004) 62(1 Suppl. 1):S47-S55.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, OBESO JA: Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitors. Neurology (2000) 55(11 Suppl. 4):S72-S77.
   PubMed Web of Science ®Google Scholar
• DURIF F: Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging (1999) 14(5):337-345.
   PubMedGoogle Scholar
• RASCOL O, GOETZ C, KOLLER W, POEWE W, SAMPAIO C: Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet (2002) 359(9317):1589-1598.
   PubMed Web of Science ®Google Scholar
• WITJAS T, KAPHAN E, AZULAY JP et al.: Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology (2002) 59(3):408-413.
   PubMed Web of Science ®Google Scholar
• NISSENBAUM H, QUINN NP, BROWN RG, TOONE B, GOTHAM AM, MARSDEN CD: Mood swings associated with the ‘on-off’ phenomenon in Parkinson’s disease. Psychol. Med. (1987) 17(4):899-904.
   PubMed Web of Science ®Google Scholar
• BLOCK G, LISS C, REINES S, IRR J, NIBBELINK D: Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur. Neurol. (1997) 37(1):23-27.
   PubMed Web of Science ®Google Scholar
• HUTTON JT, MORRIS JL, BUSH DF, SMITH ME, LISS CL, REINES S: Multicenter controlled study of Sinemet CR versus Sinemet (25/100) in advanced Parkinson’s disease. Neurology (1989) 39(11 Suppl. 2):67-72.
   PubMedGoogle Scholar
• JENSEN NO, DUPONT E, HANSEN E, MIKKELSEN B, MIKKELSEN BO: A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance. Acta Neurol. Scand. (1988) 77(5):422-425.
   PubMedGoogle Scholar
• JENSEN NO, DUPONT E, HANSEN E, MIKKELSEN B, MIKKELSEN BO: Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment. Eur. Neurol. (1987) 27(Suppl. 1):68-72.
   PubMedGoogle Scholar
• OBESO JA, OLANOW CW, NUTT JG: Levodopa motor complications in Parkinson’s disease. Trends Neurosci. (2000) 23(10 Suppl.):S2-S7.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, STOCCHI F: COMT inhibitors in Parkinson’s disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology (2004) 62(1 Suppl. 1):S72-S81.
   Web of Science ®Google Scholar
• MÜLLER T, ERDMANN C, BREMEN D et al.: Impact of gastric emptying on levodopa pharmacokinetics in Parkinson’s disease patients. Clin. Neuropharmacol. (2006) 29(2):61-67.
   PubMed Web of Science ®Google Scholar
• CHASE TN, OH JD: Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. (2000) 47(4 Suppl. 1):S122-S129.
   PubMedGoogle Scholar
• MÜLLER T, ERDMANN C, MUHLACK S et al.: Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. J. Neural Transm. (2006) [Epub ahead of print].
   Google Scholar
• MÜLLER T, ERDMANN C, MUHLACK S, BREMEN D, PRZUNTEK H, WOITALLA D: Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov. Disord. (2006) 21(3):332-336.
   PubMed Web of Science ®Google Scholar
• MACLEOD AD, COUNSELL CE, IVES N, STOWE R: Monoamine oxidase B inhibitors for early Parkinson’s disease. Cochrane. Database. Syst. Rev. (2005(3):CD004898.
   Google Scholar
• PARKINSON STUDY GROUP: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson’s disease and motor fluctuations: the PRESTO study. Arch. Neurol. (2005) 62(2):241-248.
   PubMed Web of Science ®Google Scholar
• RASCOL O, BROOKS DJ, MELAMED E, OERTEL W, POEWE W, STOCCHI F, TOLOSA E: Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet (2005) 365(9463):947-954.
   PubMed Web of Science ®Google Scholar
• DEWEY RB Jr: Management of motor complications in Parkinson’s disease. Neurology (2004) 62(6 Suppl. 4):S3-S7.
   PubMed Web of Science ®Google Scholar
• LUQUIN MR, SCIPIONI O, VAAMONDE J, GERSHANIK O, OBESO JA: Levodopa-induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov. Disord. (1992) 7(2):117-124.
   PubMed Web of Science ®Google Scholar
• MARCONI R, LEFEBVRE-CAPARROS D, BONNET AM, VIDAILHET M, DUBOIS B, AGID Y: Levodopa-induced dyskinesias in Parkinson’s disease phenomenology and pathophysiology. Mov. Disord. (1994) 9(1):2-12.
   PubMed Web of Science ®Google Scholar
• FAHN S: The spectrum of levodopa-induced dyskinesias. Ann. Neurol. (2000) 47(4 Suppl. 1):S2-S9.
   PubMed Web of Science ®Google Scholar
• CUBO E, GRACIES JM, BENABOU R et al.: Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch. Neurol. (2001) 58(9):1379-1382.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J: Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov. Disord. (2005) 20(Suppl. 11):S11-S16.
   Google Scholar
• BEZARD E, BROTCHIE JM, GROSS CE: Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. (2001) 2(8):577-588.
   PubMed Web of Science ®Google Scholar
• BEZARD E, FERRY S, MACH U et al.: Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. (2003) 9(6):762-767.
   PubMed Web of Science ®Google Scholar
• JENNER P: A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology (2003) 61(11 Suppl. 6):S32-S38.
   PubMedGoogle Scholar
• OBESO JA, RODRIGUEZ-OROZ MC, CHANA P, LERA G, RODRIGUEZ M, OLANOW CW: The evolution and origin of motor complications in Parkinson’s disease. Neurology (2000) 55(11 Suppl. 4):S13-S20.
   PubMedGoogle Scholar
• OBESO JA, RODRIGUEZ-OROZ MC, RODRIGUEZ M, DELONG MR, OLANOW CW: Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann. Neurol. (2000) 47(4 Suppl. 1):S22-S32.
   PubMed Web of Science ®Google Scholar
• BEJJANI BP, ARNULF I, DEMERET S, DAMIER P, BONNET AM, HOUETO JL, AGID Y: Levodopa-induced dyskinesias in Parkinson’s disease: is sensitization reversible? Ann. Neurol. (2000) 47(5):655-658.
   Web of Science ®Google Scholar
• BORAUD T, BEZARD E, BIOULAC B, GROSS CE: Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain (2001) 124(Pt 3):546-557.
   PubMed Web of Science ®Google Scholar
• VIDAILHET M, BONNET AM, MARCONI R, DURIF F, AGID Y: The phenomenology of L-dopa-induced dyskinesias in Parkinson’s disease. Mov. Disord. (1999) 14 (Suppl. 1):13-18.
   PubMedGoogle Scholar
• VERHAGEN ML, DEL DOTTO P, BLANCHET PJ, VAN DEN MP, CHASE TN: Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Amino Acids (1998) 14(1-3):75-82.
   PubMedGoogle Scholar
• JENNER P: Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol. (2000) 247(Suppl. 2):II43-II50.
   PubMedGoogle Scholar
• MELAMED E, HEFTI F, LIEBMAN J, SCHLOSBERG AJ, WURTMAN RJ: Serotonergic neurones are not involved in action of L-dopa in Parkinson’s disease. Nature (1980) 283(5749):772-774.
   PubMedGoogle Scholar
• RASCOL O: L-dopa-induced peak-dose dyskinesias in patients with Parkinson’s disease: a clinical pharmacologic approach. Mov. Disord. (1999) 14(Suppl. 1):19-32.
   PubMedGoogle Scholar
• RASCOL O, FABRE N: Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin. Neuropharmacol. (2001) 24(6):313-323.
   PubMedGoogle Scholar
• PRZUNTEK H, WELZEL D, GERLACH M et al.: Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J. Neural Transm. Gen. Sect. (1996) 103(6):699-715.
   PubMed Web of Science ®Google Scholar
• RASCOL O, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. (2000) 342(20):1484-1491.
   PubMed Web of Science ®Google Scholar
• NYHOLM D, JANSSON R, WILLOWS T, REMAHL IN: Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology (2005) 65(9):1506-1507.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, VACCA L, DE PANDIS MF, BARBATO L, VALENTE M, RUGGIERI S: Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurol. Sci. (2001) 22(1):93-94.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, RUGGIERI S, VACCA L, OLANOW CW: Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain (2002) 125(Pt 9):2058-2066.
   PubMed Web of Science ®Google Scholar
• LOZANO AM, LANG AE, LEVY R, HUTCHISON W, DOSTROVSKY J: Neuronal recordings in Parkinson’s disease patients with dyskinesias induced by apomorphine. Ann. Neurol. (2000) 47(4 Suppl. 1):S141-S146.
   PubMedGoogle Scholar
• HELY MA, MORRIS JG, REID WG, TRAFFICANTE R: Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. (2005) 20(2):190-199.
   PubMed Web of Science ®Google Scholar
• KUMAR N, VAN GERPEN JA, BOWER JH, AHLSKOG JE: Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Mov. Disord. (2005) 20(3):342-344.
   PubMed Web of Science ®Google Scholar
• MAZZELLA L, YAHR MD, MARINELLI L, HUANG N, MOSHIER E, DI ROCCO A: Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson’s disease on L-dopa monotherapy. Parkinsonism Relat Disord. (2005) 11(3):151-155.
   PubMedGoogle Scholar
• PECHEVIS M, CLARKE CE, VIEREGGE P et al.: Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur. J. Neurol. (2005) 12(12):956-963.
   PubMed Web of Science ®Google Scholar
• VAN GERPEN JA, KUMAR N, BOWER JH, WEIGAND S, AHLSKOG JE: Levodopa-associated dyskinesia risk among Parkinson’s disease patients in Olmsted County, Minnesota, 1976-1990. Arch. Neurol. (2006) 63(2):205-209.
   PubMedGoogle Scholar
• AHLSKOG JE, MUENTER MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. (2001) 16(3):448-458.
   PubMed Web of Science ®Google Scholar
• DODEL RC, SINGER M, KOHNE-VOLLAND R et al.: The economic impact of Parkinson’s disease. An estimation based on a 3- month prospective analysis. Pharmacoeconomics (1998) 14(3):299-312.
   PubMed Web of Science ®Google Scholar
• GOETZ CG: Rating scales for dyskinesias in Parkinson’s disease. Mov. Disord. (1999) 14(Suppl. 1):48-53.
   PubMedGoogle Scholar
• HAUSER RA, FRIEDLANDER J, ZESIEWICZ TA et al.: A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin. Neuropharmacol. (2000) 23(2):75-81.
   PubMed Web of Science ®Google Scholar
• HAUSER RA, DECKERS F, LEHERT P: Parkinson’s disease home diary: further validation and implications for clinical trials. Mov. Disord. (2004) 19(12):1409-1413.
   PubMed Web of Science ®Google Scholar
• SCHRAG A, QUINN N: Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain (2000) 123(Pt 11):2297-2305.
   PubMed Web of Science ®Google Scholar
• DAMIANO AM, MCGRATH MM, WILLIAN MK et al.: Evaluation of a measurement strategy for Parkinson’s disease: assessing patient health-related quality of life. Qual. Life Res. (2000) 9(1):87-100.
   PubMed Web of Science ®Google Scholar
• SCHRAG A, JAHANSHAHI M, QUINN N: How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov. Disord. (2000) 15(6):1112-1118.
   PubMed Web of Science ®Google Scholar
• CHAPUIS S, OUCHCHANE L, METZ O, GERBAUD L, DURIF F: Impact of the motor complications of Parkinson’s disease on the quality of life. Mov. Disord. (2005) 20(2):224-230.
   PubMed Web of Science ®Google Scholar
• LEPEN C, WAIT S, MOUTARD-MARTIN F, DUJARDIN M, ZIEGLER M: Cost of illness and disease severity in a cohort of French patients with Parkinson’s disease. Pharmacoeconomics (1999) 16(1):59-69.
   PubMed Web of Science ®Google Scholar
• FAHN S: Is levodopa toxic? Neurology (1996) 47(6 Suppl. 3):S184-S195.
   PubMed Web of Science ®Google Scholar
• MURER MG, DZIEWCZAPOLSKI G, MENALLED LB et al.: Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. (1998) 43(5):561-575.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson’s disease progression. JAMA (2002) 287(13):1653-1661.
   PubMedGoogle Scholar
• WHONE AL, WATTS RL, STOESSL AJ et al.: Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. (2003) 54(1):93-101.
   PubMed Web of Science ®Google Scholar
• GOETZ CG, POEWE W, RASCOL O, SAMPAIO C: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov. Disord. (2005) 20(5):523-539.
   PubMed Web of Science ®Google Scholar
• OERTEL WH, WOLTERS E, SAMPAIO C et al.: Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov. Disord. (2006) 21(3):343-353.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: A controlled, randomized, delayed-start study of rasagiline in early Parkinson’s disease. Arch. Neurol. (2004) 61(4):561-566.
   PubMedGoogle Scholar
• HUBBLE JP: Long-term studies of dopamine agonists. Neurology (2002) 58(4 Suppl. 1):S42-S50.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Pramipexole versus levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. Parkinson Study Group. JAMA (2000) 284(15):1931-1938.
   PubMedGoogle Scholar
• KORCZYN AD, THALAMAS C, ADLER CH: Dosing with ropinirole in a clinical setting. Acta Neurol. Scand. (2002) 106(4):200-204.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, VACCA L, RUGGIERI S, OLANOW CW: Intermittent versus continuous levodopa administration in patients with advanced Parkinson’s disease: a clinical and pharmacokinetic study. Arch. Neurol. (2005) 62(6):905-910.
   PubMed Web of Science ®Google Scholar
• GERLACH M, VAN DEN BM, BLAHA C, BREMEN D, RIEDERER P: Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 370(5):388-394.
   PubMed Web of Science ®Google Scholar
• KOLLER WC, HUTTON JT, TOLOSA E, CAPILLDEO R: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5- year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology (1999) 53(5):1012-1019.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, WATTS RL, KOLLER WC: An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology (2001) 56(11 Suppl. 5):S1-S88.
   PubMed Web of Science ®Google Scholar
• CROSBY NJ, DEANE KH, CLARKE CE: Amantadine for dyskinesia in Parkinson’s disease. Cochrane. Database. Syst. Rev. (2003) (2):CD003467.
   Google Scholar
• METMAN LV, DEL DOTTO P, LEPOOLE K, KONITSIOTIS S, FANG J, CHASE TN: Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol. (1999) 56(11):1383-1386.
   PubMed Web of Science ®Google Scholar
• VERHAGEN ML, DEL DOTTO P, VAN DEN MP, FANG J, MOURADIAN MM, CHASE TN: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease [see comments]. Neurology (1998) 50(5):1323-1326.
   PubMed Web of Science ®Google Scholar
• DURIF F, DEBILLY B, GALITZKY M, MORAND D, VIALLET F, BORG M, THOBOIS S, BROUSSOLLE E, RASCOL O: Clozapine improves dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Neurology (2004) 62(3):381-388.
   PubMed Web of Science ®Google Scholar
• DE GASPARI D, SIRI C, LANDI A, CILIA R et al.: Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry (2006) 77(4):450-453.
   PubMed Web of Science ®Google Scholar
• LYONS KE, PAHWA R: Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson’s disease. J. Neurosurg. (2006) 104(4):502-505.
   PubMed Web of Science ®Google Scholar
• PAHWA R, LYONS KE, WILKINSON SB et al.: Long-term evaluation of deep brain stimulation of the thalamus. J. Neurosurg. (2006) 104(4):506-512.
   PubMed Web of Science ®Google Scholar
• PAHWA R, FACTOR SA, LYONS KE et al.: Practice parameter: treatment of Parkinson’s disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006) [Epub ahead of print].
   Google Scholar
• JOHNSTON TH, BROTCHIE JM: Drugs in development for Parkinson’s disease. Curr. Opin. Investig. Drugs (2004) 5(7):720-726.
   PubMedGoogle Scholar
• BARTOSZYK GD, VAN AMSTERDAM C, GREINER HE, RAUTENBERG W, RUSS H, SEYFRIED CA: Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J. Neural Transm. (2004) 111(2):113-126.
   PubMedGoogle Scholar
• BIBBIANI F, OH JD, CHASE TN: Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology (2001) 57(10):1829-1834.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, DAMIER P, GOETZ CG et al.: Multicenter, open-label, trial of sarizotan in Parkinson’s disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. (2004) 27(2):58-62.
   PubMed Web of Science ®Google Scholar
• RABINER EA, GUNN RN, WILKINS MR, SEDMAN E, GRASBY PM: Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J. Psychopharmacol. (2002) 16(3):195-199.
   PubMed Web of Science ®Google Scholar
• BARA-JIMENEZ W, SHERZAI A, DIMITROVA T et al.: Adenosine A(2A) receptor antagonist treatment of Parkinson’s disease. Neurology (2003) 61(3):293-296.
   PubMed Web of Science ®Google Scholar
• HAUSER RA, HUBBLE JP, TRUONG DD: Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology (2003) 61(3):297-303.
   PubMed Web of Science ®Google Scholar
• JENNER P: Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Expert. Opin. Investig. Drugs (2005) 14(6):729-738.
   PubMed Web of Science ®Google Scholar
• KANDA T, JACKSON MJ, SMITH LA et al.: Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. (2000) 162(2):321-327.
   PubMed Web of Science ®Google Scholar
• JOHNSTON TH, BROTCHIE JM: Drugs in development for Parkinson’s disease. Curr. Opin. Investig. Drugs (2004) 5(7):720-726.
   PubMedGoogle Scholar
• SAVOLA JM, HILL M, ENGSTROM M, MERIVUORI H et al.: Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Mov. Disord. (2003) 18(8):872-883.
   PubMed Web of Science ®Google Scholar
• JURANYI Z, SZIRAY N, MARKO B, LEVAY G, HARSING LG Jr: AMPA receptor blockade potentiates the stimulatory effect of L-DOPA on dopamine release in dopamine-deficient corticostriatal slice preparation. Crit. Rev. Neurobiol. (2004) 16(1-2):129-139.
   PubMedGoogle Scholar
• KONITSIOTIS S, BLANCHET PJ, VERHAGEN L, LAMERS E, CHASE TN: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology (2000) 54(8):1589-1595.
   PubMed Web of Science ®Google Scholar
• TOUSI B, SUBRAMANIAN T: The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson’s disease. Parkinsonism Relat. Disord. (2005) 11(5):333-334.
   PubMedGoogle Scholar
• ZESIEWICZ TA, SULLIVAN KL, MALDONADO JL, TATUM WO, HAUSER RA: Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson’s disease. Mov. Disord. (2005) 20(9):1205-1209.
   PubMed Web of Science ®Google Scholar
• LOVE R: D3 receptors and levodopa-induced dyskinesia. Lancet Neurol. (2003) 2(7):389.
   PubMedGoogle Scholar
• LI Z, ICHIKAWA J, HUANG M, PRUS AJ, DAI J, MELTZER HY: ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (2005) 183(2):144-153.
   PubMed Web of Science ®Google Scholar
• VANOVER KE, WEINER DM, MAKHAY M et al.: Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2a receptor inverse agonist. J. Pharmacol. Exp. Ther. (2006) 317(2):910-918.
   PubMed Web of Science ®Google Scholar
• FACTOR SA: Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology (2004) 62(6 Suppl. 4):S12-S17.
   PubMed Web of Science ®Google Scholar
• NYHOLM D, NILSSON REMAHL AI, DIZDAR N et al.: Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson’s disease. Neurology (2005) 64(2):216-223.
   PubMed Web of Science ®Google Scholar
• BERNEY A, VINGERHOETS F, PERRIN A et al.: Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients. Neurology (2002) 59(9):1427-1429.
   PubMed Web of Science ®Google Scholar